Castle Biosciences, Inc. has grown revenue 29% a year over three years and 36% a year over five. Revenue growth, 3-year annual rate: +29% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +36%, growth has slowed since the five-year average. Years of annual history on file: 8, FY2018 to FY2025, as filed.

CSTLCastle Biosciences, Inc.

Healthcare

$33.72+47% 1Y

$33.72

$18.1552 weeks$43.04

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin narrowing (−2.9 points).

1 to watch, 1 neutral, 1 without data

Revenue trend+3% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +36% a year.

Margin direction−2.9 points operating

Trailing-twelve-month operating margin, -9.4% now against -6.5% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CSTL growing?

Castle Biosciences, Inc. has grown revenue 29% a year over three years and 36% a year over five.

+29%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +36%
Revenue growth, 5-year rate · +29% over three · growth has slowed since the five-year average
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›